Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology

 Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology

Paige.AI Receives FDA’s Breakthrough Designation for its Artificial Intelligence in Pathology

Shots:

  • FDA grants BT designation to Paige.AI to develop AI in computational pathology for the diagnosis and treatment of cancer including prostate cancer
  • The FDA’s BT designation is granted for technologies that provide effective diagnosis and treatment for life-threatening diseases
  • Paige.AI is based on Fuch’s technology, works with the de-identified dataset to develop AI portfolio targeting multiple cancer across the world

Click here to read full press release/ article | Ref: Business Wire | Image: Medium